

October 20, 2014



Final Reminder Related to Actinium's Key Opinion Leader Event Focused on Emerging Therapies for Acute Myeloid Leukemia on October 21st in New York City

Joseph G. Jurcic, MD, Director of the Hematologic Malignancies at Columbia University Medical Center Will Be the Featured Speaker

NEW YORK, NY -- (Marketwired) -- 10/20/14 -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today issued a final reminder regarding its previously announced Key Opinion Leader breakfast which will be held on Tuesday, October 21, 2014 from 8 a.m.-9:30 a.m. Eastern Time in New York City. A live webcast of the event will also be available.

The meeting will feature Joseph G. Jurcic, MD, Professor of Medicine and Director of the Hematologic Malignancies Section of the Hematology/Oncology Division at Columbia University Medical Center. He had previously served as an Attending Physician in the Leukemia Service at Memorial Sloan-Kettering Cancer Center for 18 years. His main areas of expertise are in the treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome. Most recently, his research has focused on the use of radioimmunotherapies using alpha particle-emitting radionuclides to eradicate minimal disease. Dr. Jurcic has authored or co-authored more than 80 articles and book chapters and has been the principal investigator on over 25 clinical trials. He is the recipient of the Louis and Allston Boyer Young Investigator Award for Distinguished Achievement in Biomedical Research.

Dr. Dragan Cicic, Actinium's Chief Medical Officer, will also provide a brief overview of the Company's two lead development programs -- Iomab™-B which is preparing to enter a single, pivotal, multicenter Phase 3 clinical study in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55, and Actimab-A, which is currently in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

A live webcast of the event will be available at <http://lifesci.rampard.com/20141021/>. A live webcast of the event will also be available in the Investors section of the Company's website at www.actiniumpharma.com. The event is intended for institutional investors and sell-side

analysts only. If you wish to attend in person, please contact Veronica Molina at 212-915-2567 or via e-mail at vmolina@lifesciadvisors.com.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical lomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of lomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Actinium Pharmaceuticals, Inc.
Evan Smith, CFA
VP Investor Relations and Finance
(646) 840-5442
esmith@actiniumpharma.com

Source: Actinium Pharmaceuticals